Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading statement - Autumn 2025

23 Oct 2025 07:00

RNS Number : 4657E
Synthomer PLC
23 October 2025
 

Synthomer plcAutumn 2025 trading statement

Resilient performance in soft end-market environment

 

Synthomer plc ('Synthomer' or the 'Group') today issues a scheduled update on trading for the third quarter of 2025.

 

· Resilient Q3 2025 performance against a continuing soft market backdrop, led by Adhesive Solutions

· Additional self-help actions delivering an increasing benefit through the second half, mitigating subdued end-market conditions following trade tensions

· Expect Continuing EBITDA for 2025 to be similar to 2024

· Continued focus on strategic transformation and broadened divestment programme

 

Q3 2025 saw a continuation of soft demand across a number of end markets, which the Group was largely able to mitigate through our additional self-help initiatives. The Adhesive Solutions division continued to regain share and enhance margins, supported by our investment in increased APO capacity for adhesive applications at our Texas facility, which came onstream in July. Health & Protection volumes for the medical glove market remained subdued in the period, although our customers are increasingly confident of benefiting from their improved competitiveness in the US medical glove market following tariff changes. End markets in the Coatings & Construction Solutions division were more varied in the period - improving construction and relatively stable consumer sub-segments were offset by a slowdown in coatings demand particularly in the USA and low levels of oil and gas drilling activity affecting the energy solutions business. As anticipated, our 'in region, for region' manufacturing strategy means we are experiencing limited direct tariff impact which we are largely offsetting through surcharges, but we remain mindful that ongoing uncertainties around the global trade environment continue to create volatility in end-market demand.

 

As previously described, the Group has responded to the market environment by identifying additional rationalisation and cost efficiency opportunities. The new programme announced in August, which includes the removal of around 250 roles globally from the organisation, has now largely been completed and is on track to deliver c.£20-25m in savings on an annual run-rate basis by 2026. This programme supplements the previously identified benefits from robust pricing and the efficiency, reliability improvement and other 'self-help' actions implemented in 2025.

 

Alongside operational execution, we continue to focus on the strategic transformation of the Group and on strengthening our balance sheet. Having divested William Blythe in May, we continue to progress the Group's broadened divestment pipeline in order to accelerate the Group's deleveraging and simplify the portfolio further. Focus on cash generation is helping to ensure that the Group retains ample committed liquidity (after repayment of the stub 2025 bonds on 2 July 2025).

 

With our additional self-help actions largely mitigating the soft end-market demand conditions that we anticipate will persist for the remainder of 2025, we expect Continuing Group EBITDA for the year to be similar to the £143m reported in 2024, and expect a cash inflow in H2 to result in broadly neutral Free Cash Flow for the year. As we begin to look to 2026, we anticipate progress in Group earnings and cash generation as a result of full year contributions from our self-help actions and product investments.

 

Commenting, Synthomer CEO Michael Willome said:

"With ongoing global geopolitical and tariff-related turbulence continuing to unbalance demand and supply in our end markets, we have sharpened our focus on what we can control - expanding our cost saving programme, accelerating the transformation of our business portfolio and allocating resources even more rigorously to strengthen our financial position. We have clear commercial, operational and strategic plans in place, which are contributing to greater resilience and a stronger portfolio mix with considerable operating leverage to end-market demand recovery. As such, we remain confident in our objective to double Synthomer's recent earnings levels in the medium term, through our cost actions and strategy of focusing the business on market-leading speciality products with sustainable, differentiated benefits for global end-users."

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,900 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £2.0bn in continuing revenue in 2024, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power.

 

In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets.

 

Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn.

 

Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56. Classification as per DTR 6 Annex 1R: 3.1.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFDIVLFFIE
Date   Source Headline
29th Sep 20227:00 amRNSTrading update
23rd Sep 20229:23 amRNSHolding(s) in Company
12th Sep 20223:27 pmRNSHolding(s) in Company
6th Sep 20228:15 amRNSHolding(s) in Company
12th Aug 20229:22 amRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSDirector/PDMR Shareholding
9th Aug 20224:09 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSDirector/PDMR Shareholding
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.